Actively Recruiting
Prognosis of Cerebral Small Vessel Disease - a Prospective Cohort Study (PRO-SVD)
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2023-03-08
900
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the prognosis of cerebral small vessel disease (SVD), focusing on how the type of SVD and initial symptoms affect patient outcomes. This observational cohort study aims to understand the risks of different events such as strokes, hemorrhages, and cardiovascular death among patients with various forms of SVD, including hypertensive deep perforator arteriolopathy, cerebral amyloid angiopathy, and other genetic or sporadic types like CADASIL. Participants in this study are patients diagnosed with symptomatic SVD types, including those with intracerebral hemorrhage, ischemic stroke, cognitive impairment, or severe radiological signs. The study observes these patients over time without administering specific treatments, tracking clinical and radiological outcomes related to their SVD condition. During the study, participants will be monitored for events including intracerebral hemorrhage, ischemic stroke, cardiovascular death, other intracranial bleeding, neurological attacks, cognitive decline, new vascular disease onset, and functional outcomes over one year. Researchers will collect data through follow-up visits to assess these outcomes and better understand SVD progression and risks.
CONDITIONS
Brief Title
Prognosis of Cerebral Small Vessel Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed hypertensive deep perforator arteriolopathy with symptoms such as intracerebral hemorrhage, ischemic stroke, cognitive impairment, or severe radiological signs (Fazekas 65II)
- Diagnosed cerebral amyloid angiopathy (CAA) with symptoms such as intracerebral hemorrhage, cortical superficial siderosis, amyloid spells, cognitive impairment, or severe radiological signs (CMB 652)
- Diagnosed other small vessel disease including CADASIL or other sporadic or genetic types
- Aged 16 years or older
You will not qualify if you...
- Life expectancy less than 6 months due to causes unrelated to small vessel disease (e.g., cancer)
- Unlikely to attend follow-up visits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 year
Participants are observed over time to monitor progression and outcomes related to cerebral small vessel disease.
Trial Site Locations
Total: 1 location
1
Department of Neurology, Inselspital Bern University Hospital
Bern, Switzerland, 3010
Actively Recruiting
Research Team
M
Marianne Kormann
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here